Publications by authors named "Elena Gallia"

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive degeneration of motor neurons (MNs). Astrocytes display a toxic phenotype in ALS, which results in MN damage. Glutamate (Glu)-mediated excitotoxicity and group I metabotropic glutamate receptors (mGluRs) play a pathological role in the disease progression.

View Article and Find Full Text PDF
Article Synopsis
  • ALS is a fatal neurodegenerative disease characterized by motor neuron loss, with unclear mechanisms driving selective neuron death, complicating treatment efforts.
  • Group I metabotropic glutamate receptors (mGluR1 and mGluR5) contribute to excitotoxicity in ALS, with studies showing that reducing their expression improves survival and motor function in SOD1 mouse models.
  • Research using mGluR1 and mGluR5 null mice revealed that reducing mGluR5 leads to delayed disease progression and better motor skills, indicating its potential as a therapeutic target against ALS.
View Article and Find Full Text PDF

Amyotrophic lateral sclerosis (ALS) is an adult-onset fatal neurodegenerative disease characterized by muscle wasting, weakness, and spasticity due to a progressive degeneration of cortical, brainstem, and spinal motor neurons. The etiopathological causes are still largely obscure, although astrocytes definitely play a role in neuronal damage. Several mechanisms have been proposed to concur to neurodegeneration in ALS, including mitochondrial dysfunction.

View Article and Find Full Text PDF

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder due to loss of upper and lower motor neurons (MNs). The mechanisms of neuronal death are largely unknown, thus prejudicing the successful pharmacological treatment. One major cause for MN degeneration in ALS is represented by glutamate(Glu)-mediated excitotoxicity.

View Article and Find Full Text PDF

Abnormal Glu release occurs in the spinal cord of SOD1(G93A) mice, a transgenic animal model for human ALS. Here we studied the mechanisms underlying Glu release in spinal cord nerve terminals of SOD1(G93A) mice at a pre-symptomatic disease stage (30days) and found that the basal release of Glu was more elevated in SOD1(G93A) with respect to SOD1 mice, and that the surplus of release relies on synaptic vesicle exocytosis. Exposure to high KCl or ionomycin provoked Ca(2+)-dependent Glu release that was likewise augmented in SOD1(G93A) mice.

View Article and Find Full Text PDF